Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Grandfield & Dodd LLC

Grandfield & Dodd LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 35.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,067 shares of the medical equipment provider’s stock after selling 12,165 shares during the quarter. Grandfield & Dodd LLC’s holdings in Zimmer Biomet were worth $1,984,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after acquiring an additional 192,517 shares during the last quarter. Dodge & Cox increased its stake in shares of Zimmer Biomet by 5.1% in the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after acquiring an additional 1,118,710 shares during the last quarter. Capital International Investors increased its stake in shares of Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after acquiring an additional 778,467 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Zimmer Biomet by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock worth $468,821,000 after acquiring an additional 36,611 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Zimmer Biomet by 1.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,789,200 shares of the medical equipment provider’s stock worth $373,239,000 after acquiring an additional 58,335 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent research reports. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company cut their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. JPMorgan Chase & Co. cut their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Finally, Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $82.46 on Friday. The stock has a market cap of $15.95 billion, a PE ratio of 21.42, a P/E/G ratio of 1.91 and a beta of 0.48. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The stock has a fifty day simple moving average of $87.96 and a 200-day simple moving average of $90.63.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.